In the original publication [1], there was a mistake in Figure 6A. When the IVIS images of two mice in JK10 group day 17 were cropped from the original larger image to fit with the layout, a mistake occurred so that one JK10 mouse was replaced with a JK11 mouse. The analyzed data were correct; as were Figure 6B–D. Only the image of the individual mouse was wrong. The corrected Figure 6 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
![View Image - Figure 6. CD28 and 4-1BB CAR T cells inhibit tumor growth in vivo. (A) Bioluminescence images of individual mice at multiple time points in a subcutaneous tumor model. NSG mice were engrafted subcutaneously on both hind legs with 2 × 106 luciferase expressing 22Rv1 prostate cancer cells. On days 10 and 17, the mice were treated with 1 × 107 non-transduced (NT) T cells (Ntumor = 6) or CD28 CAR T cells (Ntumor = 12) and 4-1BB CAR T cells (Ntumor = 12) by intravenous injection. Bioluminescence signals of individual mice were measured at indicated time points (days after tumor engraftment). (B) Tumor growth is measured once a week by bioluminescence IVIS imaging. The data are presented as the mean ± SEM of tumors in each group. (C) Bioluminescence signals (mean ± SEM) 38 days after tumor engraftment. Statistical analyses in (B,C) were performed with the Mann–Whitney U test. NS (not significant), ** p [less than] 0.001. (D) The body weight of the mice was measured once per week after the first treatment with T cells on day 10. Error bars indicate SD.](https://media.proquest.com/media/hms/THUM/2/ZjZ4a?_a=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%3D%3D&_s=S8du8O7zHRD%2BYVYnkWbrwtVzj3k%3D "View Image - Figure 6. CD28 and 4-1BB CAR T cells inhibit tumor growth in vivo. (A) Bioluminescence images of individual mice at multiple time points in a subcutaneous tumor model. NSG mice were engrafted subcutaneously on both hind legs with 2 × 106 luciferase expressing 22Rv1 prostate cancer cells. On days 10 and 17, the mice were treated with 1 × 107 non-transduced (NT) T cells (Ntumor = 6) or CD28 CAR T cells (Ntumor = 12) and 4-1BB CAR T cells (Ntumor = 12) by intravenous injection. Bioluminescence signals of individual mice were measured at indicated time points (days after tumor engraftment). (B) Tumor growth is measured once a week by bioluminescence IVIS imaging. The data are presented as the mean ± SEM of tumors in each group. (C) Bioluminescence signals (mean ± SEM) 38 days after tumor engraftment. Statistical analyses in (B,C) were performed with the Mann–Whitney U test. NS (not significant), ** p [less than] 0.001. (D) The body weight of the mice was measured once per week after the first treatment with T cells on day 10. Error bars indicate SD.")
Enlarge this image.Figure 6. CD28 and 4-1BB CAR T cells inhibit tumor growth in vivo. (A) Bioluminescence images of individual mice at multiple time points in a subcutaneous tumor model. NSG mice were engrafted subcutaneously on both hind legs with 2 × 106 luciferase expressing 22Rv1 prostate cancer cells. On days 10 and 17, the mice were treated with 1 × 107 non-transduced (NT) T cells (Ntumor = 6) or CD28 CAR T cells (Ntumor = 12) and 4-1BB CAR T cells (Ntumor = 12) by intravenous injection. Bioluminescence signals of individual mice were measured at indicated time points (days after tumor engraftment). (B) Tumor growth is measured once a week by bioluminescence IVIS imaging. The data are presented as the mean ± SEM of tumors in each group. (C) Bioluminescence signals (mean ± SEM) 38 days after tumor engraftment. Statistical analyses in (B,C) were performed with the Mann–Whitney U test. NS (not significant), ** p [less than] 0.001. (D) The body weight of the mice was measured once per week after the first treatment with T cells on day 10. Error bars indicate SD.
Reference
1. Jin, Y.; Dunn, C.; Persiconi, I.; Sike, A.; Skorstad, G.; Beck, C.; Kyte, J.A. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers. Int. J. Mol. Sci.; 2024; 25, 586. [DOI: https://dx.doi.org/10.3390/ijms25010586] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/38203757]
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Sike, Adam 1 ; Skorstad, Gjertrud 2 ; Beck, Carole 1
; Kyte, Jon Amund 3
1 Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0379 Oslo, Norway;
2 Department of Clinical Cancer Research, Oslo University Hospital, 0424 Oslo, Norway
3 Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0379 Oslo, Norway;